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enzyme in the ceramide salvage pathway, as a novel target gene of HIF-2α transcriptional activity and discovered that the HIF-2α-NEU3-ceramide axis promotes NAFLD development. Notably, we found that a specific HIF-2α inhibitor, PT2385, which is in clinical trials for the treatment of renal cancer, prevents and reverses metabolic disorders through the inhibition of intestinal HIF-2α. This work suggests that intestinal HIF-2α is a novel target for the treatment of NAFLD.
RESULTS
Intestinal HIF-2a signaling is activated in humans with obesity To investigate the potential association between HIF-2α signaling and obesity, we assessed HIF-2α expression in distal ileum biopsies from nonobese individuals and individuals with obesity by immunohistochemical staining (Fig. 1a) and western blot analysis (Fig. 1b) , revealing notably higher HIF-2α expression in humans with obesity relative to nonobese controls. The mRNA levels of DMT1 and DCYTB (officially known as CYBRD1), two genes whose transcription is targeted by HIF-2α, were also markedly upregulated in humans with obesity (Fig. 1c) . By contrast, no change was noted in HIF-1α protein expression or in the mRNA levels of its target gene PDK1 (Fig. 1a-c) . Ileum DMT1 and DCYTB mRNA levels were positively correlated with body-mass index (BMI), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) activities ( Fig. 1d and Supplementary Fig. 1a ). However, no correlation was observed for PDK1 mRNA level with any of the parameters. The human data indicated the presence of hypoxia and the activation of HIF-2α signaling in the intestine of individuals with obesity.
To test the hypothesis that the small intestines of mice fed a HFD were hypoxic, we employed the HIF-α oxygen-dependent degradation domain (ODD)-luc mice, expressing the C-terminal portion of the ODD fused to a firefly luciferase (luc) gene 16 . Under normoxic conditions, the ODD is hydroxylated, which results in ubiquitination and proteasomal degradation, whereas hypoxic stress inhibits hydroxylation, leading to the accumulation of luciferase in the hypoxic tissues. As compared to the chow-diet-treated mice, there was robust activation of the luciferase signal in the small intestines from the HFD-treated group (Fig. 1e) , which suggests that a HFD might trigger a hypoxia response in the small intestine. Consistent with the activation of HIF-2α signaling observed in humans with obesity, a rapid and selective induction in HIF-2α expression was demonstrated as early as 1 week following HFD treatment (Supplementary Fig. 1b) . A longer, 8-week treatment resulted in an augmentation in the small intestine of HIF-2α protein levels and mRNA levels encoded by the HIF-2α target genes Dmt1, Dcytb, Epo, and Fpn as compared to chowfed control mice (Fig. 1f) .
Intestine-specific HIF-2a disruption attenuated steatosis To understand the importance of intestinal HIF-2α in the development and progression of metabolic disorders and NAFLD, we treated control mice (Hif2a fl/fl ) and intestine-specific Hif2a-null (Hif2a ∆IE ) mice with a HFD for 12 weeks. Compared to the Hif2a fl/fl mice, Hif2a ∆IE mice exhibited less body-weight gain with HFD feeding ( Supplementary Fig. 2a) . A glucose-tolerance test (GTT) and insulin-tolerance test (ITT) revealed that abrogation of intestinal HIF-2α substantially improved insulin sensitivity ( Supplementary  Fig. 2b,c) . Furthermore, H&E and Oil Red O staining showed a reduction in hepatic lipid droplets in Hif2a ∆IE mice (Fig. 2a) . Hif2a ∆IE mice displayed significantly lower liver weights and liver weight-to-body weight ratios relative to controls (Fig. 2b,c) . Hepatic triglyceride levels, hepatic and serum cholesterol levels, and serum ALT levels reflecting hepatic lipotoxicity were markedly lower in Hif2a ∆IE mice, with no significant difference in serum triglyceride levels as compared to the Hif2a fl/fl mice ( Fig. 2d-h ). Relative nuclear HIF-1α intensity Figure 1 Increased HIF-2α signaling in human ileum biopsies is correlated with obesity. (a) Representative immunohistochemical staining for the expression of HIF-2α and HIF-1α in human ileum biopsies from cohort 1 (n = 6 subjects/group, 3 images/subject). (b) Representative western blot analysis of HIF-2α and HIF-1α protein expression in three individual ileum biopsies from cohort 1. n = 6/group for blot quantification. (c) mRNA expression levels of HIF-2α target gene DMT1, DCYTB, and HIF-1α target gene PDK1 in human ileum biopsies from individuals without obesity (n = 18) and with obesity (n = 17) (cohort 2). **P < 0.01, relative nonobese individuals, by two-tailed Student's t-test. (d) Heat map of the correlative analysis of DMT1, DCYTB, and PDK1 mRNAs in human ileum biopsies (cohort 2) with BMI and clinical biochemistry parameters (n = 35). Correlations were assessed by nonparametric Spearman's test. (e) The relative luciferase activities in small intestine (ileum) from ODD-luciferase transgenic mice fed a chow diet or HFD (n = 4/group). (f) Western blot analysis of HIF-2α and HIF-1α protein expression (n = 3/group) and mRNA expression analysis (n = 5/group) of their target genes in small intestine from chow-diet or HFD-fed mice (8 weeks). Data are presented as mean ± s.e.m. For box plots, the midline represents the median; box represents the interquartile range (IQR) between the first and third quartiles, and whiskers represent the lowest or highest values within 1.5 times interquartile range (IQR) from the first or third quartiles. *P < 0.05, **P < 0.01 relative to a chow diet, by two-tailed Student's t-test.
Furthermore, the mRNA expression of genes involved in fatty acid transport and anabolism (Srebp1c, Cidea, Cd36, Fabp1, Fabp4, Fasn, Scd1, and Elovl6), triglyceride synthesis (Dgat1 and Dgat2), and the lipid-droplet coat (Plin2) were all substantially reduced in Hif2a ∆IE mice as compared to controls (Fig. 2i) . By contrast, the mRNA expression of genes involved in fatty acid β-oxidation, such as Acox2, Acsl1, and Acaa1a, were moderately elevated in Hif2a ∆IE mice as compared to the control mice (Fig. 2j) . Although a 12-week-period of HFD feeding did not result in obvious inflammatory cell infiltration by microscopic examination, the expression levels of inflammatory cytokines and chemokines, such as Tnfa, Pai1, Ccl2, and Ccl3, were significantly lower in Hif2a ∆IE mice than in the controls (Fig. 2k) .
Disruption of Hif2a was restricted to the intestines of Hif2a ∆IE mice, as revealed by lower Hif2a mRNA expression in the intestine, with no changes in expression in other tissues, relative to Hif2a fl/fl mice (Supplementary Fig. 2d ). Western blot analysis further showed that the disruption of intestinal HIF-2α did not affect HIF-1α or HIF-2α protein levels in the livers of the mice fed a HFD (Supplementary Fig. 2e ). In addition, intestinal HIF-2α disruption did not affect body-weight gain nor hepatic steatosis of mice fed a chow diet, even though there was no evident steatosis in chow-fed mice ( Supplementary Fig. 2f-n (Fig. 3b) . The levels of ceramides, especially the most abundant, C16:0 ceramide, were substantially lower in the small intestines of Hif2a ∆IE mice than in those of the controls (Fig. 3c) . Similar to what was observed in the small intestine, serum ceramides were also lower in Hif2a ∆IE mice than in Hif2a fl/fl mice ( Fig. 3d and Supplementary Fig. 3a,b) . Ceramides are synthesized through three different pathways ( Fig. 3e) : a de novo pathway from palmitoyl-CoA and serine, a sphingomyelinase (SMase) pathway generated by the hydrolysis of sphingomyelin and the salvage pathway generated from the catabolism of complex sphingolipids, such as from ganglioside monosialo 3 (GM3) hydrolysis 17, 18 . Consequently, sphingomyelins and glucosylceramides, the two sources for ceramide synthesis from SMase and salvage pathways, were also evaluated. There was no notable change in the relative levels of sphingomyelins in the small intestine, and only a modest reduction in serum ( Fig. 3f and Supplementary Fig. 3c ), whereas a marked change was detected in the relative levels of glucosylceramides in Hif2a ∆IE mice ( Fig. 3g and Supplementary Fig. 3d ).
It is well established that activation of the hepatic diacylglycerol-PKC-ε pathway triggers hepatic steatosis and insulin resistance 19 . Hepatic acylcarnitine and diacylglyceride contents and PKC-ε translocation remained unaltered in the livers of Hif2a ∆IE mice as compared to in those of Hif2a fl/fl mice (C.X. and Y.L., unpublished data). The changes in ceramide metabolism in response to the inhibition of intestinal HIF-2α were due neither to altered lipid absorption, as revealed by measurements of intestine and fecal lipids by both lipid-assay kits and 1 H-NMR, nor to morphological changes of the intestine, as examined histologically (C.X., Y.T. and A.D.P. unpublished data).
Along with diminished HIF-2α signaling in the small intestine ( Supplementary Fig. 3e ), many mRNAs encoded by ceramide-synthesis-related genes, including Degs2 in the de novo pathway, Smpd1, Smpd3, Smpd4, and Enpp7 in the SMase pathway and Neu3, Glb1, and Gba2 in the salvage pathway, were significantly downregulated in Hif2a ∆IE mice as compared to in Hif2a fl/fl mice ( Supplementary Fig. 3f ,g and Fig. 3h ). The mRNAs encoded by genes involved in ceramide catabolism were at similar levels in Hif2a ∆IE mice and in controls (Supplementary Fig. 3h ).
Decreased steatosis is independent of adiposity To further exclude a decrease in adiposity as a causal factor for the observed beneficial metabolic effects after intestinal-specific HIF-2α disruption, Hif2a fl/fl and Hif2a ∆IE mice were treated with a HFD for a short duration of 1 week that did not lead to a notable alteration of body weight (Supplementary Fig. 4a) . A GTT and an ITT revealed an improvement in glucose intolerance and insulin resistance in HFD-fed Hif2a ∆IE mice as compared to those of Hif2a fl/fl mice ( Supplementary  Fig. 4b,c) . The energy expenditure was substantially enhanced in Hif2a ∆IE mice, without significant changes in cumulative food intake and ambulatory activity ( Supplementary Fig. 4d-h ). Hif2a ∆IE mice exhibited lower hepatic triglyceride levels and trended toward a reduction in serum ALT levels without significant changes in liver weights and liver weight-to-body weight ratios, hepatic and serum cholesterol levels, and serum triglyceride levels, as compared to Hif2a fl/fl mice ( Supplementary Fig. 4i-o) . Fig. 4p-r) .
Accompanied by the restrained HIF-2α signaling in the small intestine, the Neu3, Glb1 Smpd1, Smpd3, Enpp7, and Degs2 mRNAs were substantially lower in the small intestine of the Hif2α ∆IE mice as compared to floxed control mice ( Supplementary Fig. 5a-d ), but were unchanged in the liver white adipose tissue (WAT) of Hif2α ∆IE mice (C.X., unpublished data). Lipidomics analysis confirmed that small intestinal, portal and systematic ceramides were markedly diminished in Hif2a ∆IE mice ( Supplementary Fig. 5e-g ). It should be noted that the portal ceramides (which are mainly derived from the intestine) were lower to a greater degree than that of systematic ceramides (31% lower relative to 19% lower) in Hif2a ∆IE mice as compared to the floxed controls, which suggested that serum ceramide changes resulted mainly from altered ceramide synthesis in the intestine.
To explore the mechanism by which the intestinal HIF-2α-ceramide pathway affected energy expenditure, the browning-related genes of different adipose tissues were examined. As compared to the Hif2a fl/fl mice, an induction of mRNAs encoded by uncoupling protein 1 (Ucp1) and other key thermogenic genes was found in subcutaneous WAT (scWAT) from Hif2a ∆IE mice without activation of thermogenic genes in brown adipose tissue (BAT) and visceral epididymal WAT (eWAT) (Supplementary Fig. 5h-j) . Western blot analysis further confirmed the upregulation of UCP1 in scWAT of Hif2a ∆IE mice (Supplementary Fig. 5k ), and immunohistochemical analysis showed an increased number of UCP1-positive beige adipocytes in the scWAT of Hif2a ∆IE mice (Supplementary Fig. 5l ).
HIF-2a modulates ceramide synthesis through targeting Neu3
Genetic models were used to investigate whether intestinal HIF-2α activation regulated ceramide metabolism. Mice with an intestinespecific disruption of Vhl (Vhl ∆IE ) had robust activation of both HIF-1α and HIF-2α signaling, whereas mice lacking both VHL and HIF-1α (Vhl/Hif1a ∆IE ) in the intestine induced only functional HIF-2α activation 20 . Consistently, the HIF-2α signaling was markedly activated in the small intestine of Vhl/Hif1a ∆IE mice relative to Vhl/Hif1a fl/fl , as revealed by measurements of the HIF-2α target genes Dmt1 and Dcytb mRNA expression (Supplementary Fig. 6a) . A similar induction of the mRNA levels of Degs2, Smpd1, Smpd3, Smpd4, Enpp7, Neu3, Glb1, and Gba2 was observed in Vhl/Hif1a ∆IE mice ( Supplementary  Fig. 6b-d) . Neu3 mRNA expression in the small intestine was shown to be the most robust (ten-fold) induced among the genes involved in ceramide synthesis as a result of intestine HIF-2α activation (Supplementary Fig. 6d ). These alterations were completely blocked by the HIF-2α antagonist PT2385 (ref. 21) .
Induction of Neu3 was observed in both single-mutant Vhl ∆IE and double-mutant Vhl/Hif1a ∆IE mice, but not in Vhl/Hif2a ∆IE mice (Supplementary Fig. 6e-j) . Furthermore, the expression of NEU3 mRNA was notably greater in the ileum biopsies of humans with obesity relative to individuals without obesity and was positively correlated with BMI, ALT, AST, DMT1 mRNA, and DCYTB mRNA expression (Fig. 4a-f ). An upregulation of NEU3 expression was also observed in the small intestines of HFD-treated mice as compared to chowfed mice (Fig. 4g) . Lactosylceramide is the product of NEU3 and a substrate for GLB1 in the salvage pathway. Consistent with the geneexpression data, the relative abundance of lactosylceramide C16:0, the predominant lactosylceramide in intestine, was also markedly lower in the small intestine of Hif2a ∆IE mice as compared to in those of Hif2a fl/fl mice ( Supplementary Fig. 6k ), indicating that NEU3 activity was suppressed in Hif2a ∆IE mice. Western blot analysis also confirmed a reduction of NEU3 expression in the small intestine by selective HIF-2α ablation (Fig. 4h) .
There are two putative HIF-response elements (HRE) in the promoter of Neu3 (Fig. 4i) , which was analyzed by transient transfection using a Neu3 promoter luciferase reporter construct. In the intestinederived HCT116 cells, the hypoxia mimic CoCl 2 or co-transfection with a constitutively active HIF-2α triple mutant (TM) expression plasmid markedly induced the luciferase activity (Fig. 4j) . The HIF-2α TM induction of luciferase expression was further potentiated in cells incubated with CoCl 2 . HRE1 (∆HRE1) or HRE2 (∆HRE2) single-deletion constructs did not change luciferase activity, whereas the activity in both HRE (∆HRE) deletion constructs was markedly suppressed. These results demonstrated that HIF-2α directly regulated Neu3 expression, and the expression was activated with either one or both HREs. Chromatin-immunoprecipitation (ChIP) assays were then performed on cross-linked soluble chromatin isolated from the small intestines of Vhl fl/fl or Vhl ∆IE mice. Primers flanking both HREs specifically amplified the DNA sequence immunoprecipitated by the HIF-2α antibody in Vhl ∆IE mice whereas no amplification was noted in controls (Fig. 4k) , demonstrating that HIF-2α is able to bind the Neu3 HREs in vivo. Increased HIF-2α binding to the HREs in the Neu3 promoter from the small intestine was also found in HFD-fed mice relative to controls (T.Y., unpublished data).
Intestine-derived ceramides control hepatic steatosis To more definitively establish the connection between intestine ceramide metabolism with hepatic steatosis, Neu3 expression and ceramide production were investigated in HCT116 cells treated with the HIF-2α inhibitor PT2385, the NEU3 inhibitor 2,3-didehydro-N-acetyl-neuraminic acid (DANA) 22 and siNEU3. PT2385 treatment completely abolished the induction of Neu3 under hypoxia, accompanied by decreased expression of the HIF-2α target gene DMT1 and DCYTB mRNAs (Supplementary Fig. 6l) . Treatment with PT2385, siNEU3 and DANA significantly blunted hypoxia-mediated induction of ceramide levels in the intestinal cell line ( Supplementary Fig. 6m and Fig. 4l,m) . These results suggested that the activation of HIF-2α signaling resulted in elevated ceramide production primarily through increased Neu3 expression in vitro. Furthermore, oral administration of the NEU3 inhibitors DANA and naringin 23 specifically inhibited the NEU3 activity in the small intestine, but not in the liver and WAT (Supplementary Fig. 7a-c) . As a result, the small intestine and serum ceramides were substantially reduced after NEU3-inhibitor treatment as compared to vehicle (Supplementary Fig. 7d,e) . DANA and naringin treatment markedly attenuated hepatic steatosis and obesity in HFD-fed mice (Supplementary Fig. 7f-p) .
Moreover, ceramide administered by the injection of C16:0 ceramide to Hif2a ∆IE mice fed a HFD for 6 weeks resulted in increased ceramide levels in small intestine and serum that were comparable to those in vehicle-treated HFD-fed Hif2a fl/fl mice (Supplementary Fig. 8a,b) . The administration of ceramide substantially reversed the improvement in body weight and insulin resistance in HFD-fed Hif2a ∆IE mice as compared to that of Hif2a fl/fl mice ( Supplementary Fig.  8c-f) . The intestinal-specific HIF-2α-ablation mediated reduction in hepatic lipid droplets, liver weights, ratios of liver weight to body weight, hepatic triglyceride levels, hepatic cholesterol levels, 
-test. (k) In vivo
ChIP assays on small intestinal extracts from Vhl fl/fl and Vhl ∆IE mice (n = 3/group). **P < 0.01, by two-tailed Student's t-test. (l) Ceramide levels in HCT116 cells treated with vehicle, PT2385, or DANA and exposed to either vehicle or CoCl 2 (n = 5/group). **P < 0.01 relative to normoxia + vehicle, ## P < 0.01 relative to hypoxia (CoCl 2 ) + vehicle, by one-way ANOVA with Tukey's correction. (m) Ceramide levels in HCT116 cells transfected with control or siNEU3 and exposed to either vehicle and CoCl 2 (n = 5/group). **P < 0.01 versus normoxia + control, ## P < 0.01 versus hypoxia (CoCl 2 ) + control, by one-way ANOVA with Tukey's correction. Data are presented as mean ± s.e.m. For box plots, the midline represents the median; box represents the IQR between the first and third quartiles, and whiskers represent the lowest or highest values within 1.5 times IQR from the first or third quartiles.
and serum ALT levels was abrogated by ceramide administration (Fig. 5a-h) . Ceramide eliminated the downregulation of hepatic expression of Srebp1c, Cidea, Cd36, Fabp1, Fabp4, Fasn, Scd1, Elovl6, Plin2, Tnfa, Pai1, Ccl2, and Ccl3 mRNAs (Fig. 5i,j) .
PT2385 improves steatosis by inhibiting intestinal HIF-2a
To assess the role of intestinal HIF-2α in the PT2385-improved NAFLD, we treated HFD-fed Hif2α fl/fl and Hif2α ∆IE mice with vehicle or PT2385. PT2385 substantially prevented HFD-induced body-weight increase and insulin resistance in Hif2a fl/fl mice, but not in Hif2a ∆IE mice (Supplementary Fig. 9a-c) . Histology analysis showed that PT2385 eliminated hepatic lipid accumulation in HFD-fed Hif2a fl/fl mice, but had no further inhibition on Hif2α ∆IE mice (Supplementary Fig. 9d ). Hif2a ∆IE mice exhibited lower liver weights, ratios of liver weight to body weight, hepatic triglycerides, hepatic and serum cholesterol content, and ALT versus Hif2a fl/fl mice, and were unresponsive to the inhibition of PT2385 treatment (Supplementary Fig. 9e-k) . Further, small intestine and serum ceramide levels were markedly reduced by PT2385 in the Hif2a fl/fl mice, but not in the Hif2a ∆IE mice (Supplementary Fig. 9l,m) . Accordingly, the mRNA levels of Degs2, Smpd1, Smpd3, Smpd4, Enpp7, Neu3, Glb1, and Gba2 were substantially inhibited in the HFD-fed Hif2a fl/fl mice by PT2385 treatment, but remained similar in the HFD-fed Hif2α ∆IE mice (Supplementary Fig. 10a-d) . In the liver, PT2385 downregulated the mRNA expression of Srebp1c, Cidea, Cd36, Fabp4, Fasn, Scd1, Elovl6, Plin2, Tnfa, Pai1, Ccl2, and Ccl3 in the Hif2a fl/fl mice, whereas no change was found in Hif2a ∆IE mice treated with PT2385 ( Supplementary Fig. 10e,f) .
To further address whether selective inhibition of intestinal HIF-2α could be a therapeutic target for HFD-induced NAFLD, and to confirm whether it is a suitable drug target, we treated HFD-fed mice with obesity and hepatic steatosis with PT2385.
Oral administration of PT2385 resulted in reduced body weight and improved insulin sensitivity (Supplementary Fig. 11a-c) . Liver histological analysis by H&E and Oil Red O staining indicated a reduction in hepatic lipid droplets after PT2385 treatment (Fig. 6a) , which was reflected by lower liver weights, ratios of liver weight to body weight, and hepatic triglycerides relative to controls (Fig. 6b-e) . Hepatic and serum cholesterol levels, and serum ALT were markedly reduced after PT2385 treatment (Fig. 6f-h PT2385 treatment substantially inhibited HIF-2α signaling as indicated by the decreased target gene Dmt1 and Dcytb mRNAs in the small intestine (Supplementary Fig. 11d) . As a result, PT2385-treated mice exhibited lower ceramide levels in both the small intestine and serum relative to vehicle-treated mice, owing to suppressed HIF-2α signaling ( Fig. 6i and Supplementary Fig. 11e) . Consistently, the expression of mRNAs encoded by Degs2, Smpd1, Smpd3, Smpd4, Enpp7, Neu3, and Glb1 was substantially suppressed in PT2385-treated mice (Supplementary Fig. 11f,g and Fig. 6j) . Western blot confirmed the reduction of NEU3 expression by PT2385 (Fig. 6k) . Hepatic mRNA expression of the genes Srebp1c, Cidea, Cd36, Fabp3, Fabp4, Fasn, Scd1, Elovl6, Plin2, Tnfa, Pai1, Ccl2, and Ccl3 was lower in the PT2385-treatment group than in the vehicle-treated control group (Supplementary Fig. 11h,i) .
DISCUSSION
Studies with hypoxic probes indicated that there is a low pO 2 at the villi tips, and inflammation and tumors further elevate epithelial hypoxia 24 . The current study demonstrated that HFD treatment promotes HIF-2α activation; however, it does not affect HIF-1α signaling in the intestine. The precise mechanism by which a HFD activates intestinal HIF-2α signaling remains unclear. The gut-bacterial-derived shortchain fatty acids (SCFAs), notably butyrate, were reported to deplete O 2 levels and activate HIF signaling in the intestinal epithelium 25, 26 . SCFAs produced by the gut microbiota might contribute to induce intestinal HIF-2α expression and activation under the condition of HFD. Other gut-microbiota-derived metabolites from tryptophan and indole metabolic pathways activate the aryl-hydrocarbon receptor (AhR) after HFD treatment 27 . HIF-2α and AhR as heterodimeric transcription factors share the same heterodimer, partner HIF-1β. Thus, there is the potential for cross-talk between the HIF-2α and AhR signaling pathways that might influence HIF-2α signaling.
Intestinal HIF-2α depletion results in less susceptibility to HFDinduced hepatic fatty liver and obesity, accompanied by a downregulation of intestine and serum ceramide levels. The underlying mechanism revealed that intestine HIF-2α but not HIF-1α inhibition markedly suppressed intestinal-derived ceramides by directly targeting ceramide biosynthesis by the key enzyme in the ceramide salvage pathway, NEU3. Furthermore, inhibition of intestinal HIF-2α signaling by PT2385 had both preventive and therapeutic effects on NAFLD and obesity (Fig. 6l) . There is a positive correlation between HIF-2α signaling in human intestine biopsies and obesity. Considering the close link between obesity and NAFLD, these findings indicate that intestinal HIF-2α signaling is activated in obesity and NAFLD and so could be a promising therapy target in humans.
Several studies highlight the potential role for compromised epithelial barrier function and immune response in NAFLD pathogenesis 14, 28, 29 . HIF-1α and HIF-2α were shown to influence intestinal epithelial permeability and inflammation 30, 31 . HIF-1α exerts a potent protective function at the epithelial barrier by regulating adherensjunction and tight-junction genes, including claudin 1 (Cldn1), mucin 3 (Muc3), trefoil factor 1 (Tff1), and 5-ectonucleotidase (Cd73) [32] [33] [34] [35] . It was reported that HIF-2α has a dual role in barrier function. Acute activation of HIF-2α results in the maintenance of tight-junction assemblies and barrier integrity through the upregulation of creatine kinase 36 , whereas chronic activation of HIF-2α disrupts the tight junctions through an increase of caveolin 1 (ref. 37) . Several reports showed that mice with intestinal epithelial HIF-1α ablation are more susceptible to intestinal injury and inflammation, whereas HIF-1α activation leads to an anti-inflammatory response in inflammatory bowel disease 38 . Prolonged HIF-2α activation in intestinal epithelial cells triggers a spontaneous inflammatory response, whereas intestinal HIF-2α deficiency substantially reduces inflammation through the direct regulation of inflammatory mediators, including tumor necrosis factor-α, microsomal prostaglandin synthase 1, and cyclooxygenase 2 in colitis models 20, 39 . It cannot be excluded that improvement of the intestinal epithelial permeability and inflammation might contribute to the metabolic benefits of intestinal HIF-2α inhibition in the mouse model of obesity.
It is well established that there is a positive relationship between ceramide levels and metabolic diseases in humans and mice 40, 41 . In patients with NAFLD, the serum ceramide levels are markedly increased 42, 43 . A causal role of ceramides in NAFLD development was further demonstrated by using pharmacological or genetic inhibition of enzymes involved in ceramide metabolism 44 . Overexpression of acid ceramidase in either the liver or adipose tissue protects against HFD-induced hepatic lipid accumulation and insulin resistance by reducing ceramide synthesis in adipose tissue 45 . The elevated C16:0-ceramide levels induced by overexpressing ceramide synthase enzymes 6 (Cers6) leads to hepatic steatohepatitis and insulin resistance, whereas liver-or adipose-specific Cers6 disruption improves fatty liver and obesity by boosting fatty acid β-oxidation 46, 47 . Mice lacking dihydroceramide desaturase 1 (DEGS1) are also resistant to HFD-induced obesity and insulin resistance, owing to lower levels of ceramides 48 . Ceramides substantially upregulate fatty acid uptake and synthesis through direct or indirect modulation of CD36 and SREBP1C signaling, respectively 15, 46 . The lower levels of intestinal ceramide production led to less hepatic lipid accumulation in a gutmicrobiota-remodeling mouse model 15 . Beside the effects of ceramide on NAFLD, ceramide was also shown to impair beige-fat function, thereby lowering energy expenditure 49, 50 . It is also well established that enhanced energy expenditure can improve hepatic steatosis and insulin resistance in rodent models of NAFLD 51, 52 . Mice with adipocyte-specific disruption of Sptlc2 involved in the de novo ceramide-synthesis pathway displayed improved beige-fat thermogenesis and hepatic steatosis following the inhibition of adipocyte ceramide synthesis 52 . Supporting this view, the current study showed that mice lacking intestine HIF-2α are resistant to HFD-induced hepatic steatosis and obesity, which is correlated with lower intestine and serum ceramides, with suppressed fatty acid synthesis and uptake, and with higher 'beiging' and thermogenic capacity. However, expression of the fatty acid β-oxidation-related genes are not changed in the livers of Hif2a fl/fl and Hif2a ∆IE mice fed a HFD for 1 week, whereas most genes encoding fatty acid-synthesis-related enzymes are substantially downregulated in the livers of Hif2a ∆IE mice, which suggests that the HIF-2α-ceramide axis mainly regulates hepatic fatty acid synthesis.
Furthermore, intestine HIF-2α but not HIF-1α was defined as a novel regulator of the ceramide salvage pathway, as revealed by measuring Neu3, Glb1, and Gba2 mRNA expression. Notably, NEU3 catalyzes the hydrolysis of GM3 into lactosylceramides, which can be converted into glucosylceramides by GLB1, whereas GBA2 catalyzes the generation of ceramides from glucosylceramides 53 . This study revealed that Neu3 is a direct target gene of HIF-2α. Interestingly, NEU3 overexpression in liver was observed to increase hepatic lipid accumulation and liver weight 54 . In the current study, direct inhibition of intestinal NEU3 substantially ameliorated hepatic steatosis. It was demonstrated that the ceramides themselves represent a more central modulator of obesity and hepatic steatosis than glucosylceramides, lactosylceramides, or sphingomyelins 49 . Therefore, the decrease of intestine-derived ceramide levels might contribute to the improvement of NAFLD after the inhibition of intestinal HIF-2α. Besides, NEU3 was found to be an upstream activator of HIF-1α in muscle cells 55 . Although HFD treatment elevated NEU3 expression, increased expression of HIF-1α protein was not found. The cell types and differential expression of the Hif1a genes may be crucial for the regulation of HIF-1α.
HIF-2α, a bHLH-PAS domain protein, was considered undruggable until the discovery of a class of compounds, including PT2385 (ref. 21) . PT2385 is an orally bioavailable HIF-2α antagonist that specially inhibits HIF-2α transcriptional activity by allosterically blocking the heterodimerization between HIF-2α and HIF-1β, while having no effect on HIF-1α. Recent reports revealed that PT2385 and the closely related analog PT2399 inhibits tumor growth and displays better efficacy than sunitinib, a currently approved first-line antiangiogenesis drug 21, 56, 57 . PT2385 is well tolerated without toxicities in a phase 1 clinical trial to treat renal cell carcinoma. In the present study, the inhibition of intestinal HIF-2α signaling by PT2385 substantially prevents and reverses obesity and hepatic steatosis, followed by a reduction of intestine and serum ceramide levels. Thus, this study revealed an essential role for intestinal HIF-2α in regulating obesity, insulin resistance and hepatic lipid metabolism, and provided a potential therapeutic approach for treating metabolic disorders.
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